Thus, the model predicts the existence of two different regimes for the impact of tumor-produced OPG, which correspond well to experimental findings of inhibition of osteolysis by cancer cell–produced OPG [9], and stimulation of osteolysis by cancer cell–produced OPG [12]. The gene discussed is TNFRSF11B; the disease is cancer.